Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Tirzepatide is the active ingredient in Zepbound, approved by the Food and Drug Administration (FDA) specifically for weight loss. Semaglutide was initially approved under the brand name Ozempic ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are managed.

Mass General Brigham researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications, such as semaglutide or tir ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

“In the future, data comparing the benefits of tirzepatide versus semaglutide for glycemic control, obesity management, and cardiovascular outcomes will help us have more informed conversations ...